HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$3.46
Day range
$3.45 - $3.53
Year range
$1.79 - $4.72
Market cap
665.12M USD
Avg Volume
910.00K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 1.34M | -71.25% |
Operating expense | 4.54M | -22.34% |
Net income | -19.72M | 1.92% |
Net profit margin | -1.47K | -241.18% |
Earnings per share | -0.14 | 15.57% |
EBITDA | -17.14M | 18.34% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 127.79M | -4.76% |
Total assets | 140.44M | -11.47% |
Total liabilities | 33.55M | -14.64% |
Total equity | 106.89M | — |
Shares outstanding | 189.49M | — |
Price to book | 6.18 | — |
Return on assets | -29.07% | — |
Return on capital | -35.87% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -19.72M | 1.92% |
Cash from operations | -20.74M | 4.81% |
Cash from investing | -11.99M | -214.93% |
Cash from financing | 1.78M | 5.59% |
Net change in cash | -30.94M | -220.11% |
Free cash flow | -10.88M | 21.66% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
73
